Filing Summary
Entity and period: The supplied filing is Zafgen, Inc.’s unaudited Form 10-Q for the three months ended March 31, 2018, filed May 10, 2018. This differs from the request metadata naming Larimar Therapeutics, Inc.; investors should verify the issuer and filing identity.
Business context
Zafgen was a clinical-stage biopharmaceutical company developing MetAP2 inhibitors for metabolic diseases. Its lead candidate, ZGN-1061, was in Phase 2 development for type 2 diabetes; ZGN-1258 was in IND-enabling nonclinical work for Prader-Willi syndrome (PWS). The company reported no product revenue and had not commercialized a product.
Financial performance and position
| Metric | Q1 2018 | Q1 2017 / comparison |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $12.4 million | $9.7 million; up $2.8 million |
| General and administrative expense | $3.3 million | $3.6 million; down $0.3 million |
| Total operating expenses | $15.7 million | $13.3 million; up $2.4 million |
| Net loss | $16.0 million | $13.0 million |
| Basic and diluted loss per share | $0.58 | $0.48 |
| Operating cash use | $13.3 million | $11.7 million |
- R&D growth reflected $1.6 million of ZGN-1258 costs, higher discovery and screening expense, and higher unallocated costs; lower ZGN-1061 nonclinical and manufacturing expense partly offset the increases.
- Cash, cash equivalents and marketable securities totaled $89.1 million at March 31, 2018, versus $102.1 million at December 31, 2017. Cash and cash equivalents were $45.7 million; marketable securities were $43.3 million.
- Operating cash use was partly offset by $18.0 million provided by investing activities, mainly net sales and maturities of marketable securities. Financing activities provided $0.3 million. Cash and cash equivalents increased $5.0 million during the quarter.
- Total assets were $92.6 million, compared with $105.5 million at year-end 2017. Stockholders’ equity was $65.0 million, down from $78.2 million.
- Notes payable were $20.2 million, including a $20.0 million term loan principal balance. Current liabilities were $7.5 million. No revenue means a gross margin or operating margin is not meaningful.
Material changes and outlook
- Management said existing cash, cash equivalents and marketable securities were expected to fund planned operations, capital expenditures and debt repayments for at least one year from the report’s issuance. Management cautioned that estimates depend on assumptions and funds could be used sooner.
- Management expected R&D expense to increase as ZGN-1061 advanced and ZGN-1258 progressed toward clinical development; G&A expense was expected to remain relatively consistent with 2017.
- Management expected full results from the core ZGN-1061 Phase 2 trial around mid-2018 and results including a newly added 1.8 mg dose arm in early 2019. It anticipated filing a ZGN-1258 IND and beginning Phase 1 development by year-end 2018. These were forward-looking expectations, not assurances.
- In March 2018, the company reported an interim ZGN-1061 analysis indicating that the 0.9 mg dose was well tolerated, without identified safety signals, and improved glycemic control. The filing also notes an increase in A1C in some treatment groups between weeks 8 and 12; the subsequent course was unknown.
- The term loan bears a variable rate of prime plus 1.25% (4.75% prime at quarter-end), has an 8% final payment, and requires minimum liquidity and other covenants. The company reported meeting the specified liquidity requirements. The loan is secured by substantially all personal property other than intellectual property; a covenant breach or default could give lenders remedies against collateral.
Risks, contingencies and unusual items
- The company had an accumulated deficit of $305.5 million and recurring operating losses; additional financing would be needed beyond the stated runway. Financing may dilute shareholders, impose restrictions, or require licensing or partnering rights.
- Development risk is substantial: ZGN-1061 was the only candidate in clinical development. The filing emphasizes that early and interim results may not predict later outcomes and highlights prior thrombotic events associated with first-generation candidate beloranib.
- Clinical, regulatory, manufacturing, enrollment, intellectual-property and third-party CRO/contract manufacturer risks could delay or prevent development or approval. The company also cited competition, uncertain market acceptance and the uncertain size of the PWS population.
- Potential beloranib-related license obligations included up to $12.3 million in pre-commercialization milestones and up to $12.5 million in commercialization milestones, plus royalties if products are commercialized. No milestones were achieved in the quarter.
- No material claims or litigation were reported as of March 31, 2018. The filing reported no off-balance-sheet arrangements and no material changes in contractual obligations outside the ordinary course.
- Foreign-currency transaction losses were $0.1 million in Q1 2018 versus gains of $0.1 million in Q1 2017; the company did not hedge foreign-currency exposure. A hypothetical 10% adverse currency move was estimated to increase net loss by $0.2 million.
Important facts for investors to verify
- Confirm that this Zafgen filing, rather than a Larimar Therapeutics filing, is the intended document.
- Check subsequent ZGN-1061 full-trial results, including safety findings and the A1C observations, against the interim disclosure.
- Verify ZGN-1258 IND and Phase 1 timing and the progress and cost of both development programs.
- Review current liquidity, cash-burn rate, financing needs, and compliance with the term-loan liquidity tests, covenants and repayment schedule.
- Assess whether later filings disclose material changes to licensing obligations, litigation, clinical risks or the company’s stated runway.